About Paraneoplastic antigen-like protein 5
Paraneoplastic antigen-like protein 5 (PNMA5) is a protein
from Homo sapiens identified by UniProt accession
Q96PV4, 448 residues long.
MolForge cross-references it against 0 known binders and
12 disease associations.
Target properties
| Protein name | Paraneoplastic antigen-like protein 5 |
| UniProt accession | Q96PV4 |
| Gene | PNMA5 |
| Organism | Homo sapiens |
| Length | 448 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (12)
Diseases linked to this target (Open Targets).
- non-small cell lung carcinoma · score 0.08
- central nervous system cancer · score 0.04
- glioblastoma multiforme · score 0.03
- cancer · score 0.02
- Benign Ovarian Neoplasm · score 0.01
- neoplasm · score 0.01
- Carcinoma, Lewis Lung · score 0.01
- hepatocellular carcinoma · score 0.00
- Neoplasm of the lung · score 0.00
- glioblastoma · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96PV4-F1 | alphafold | PREDICTED | 69.56 | — |
Amino-acid sequence (448 residues)
MALTLLEDWC KGMDMDPRKA LLIVGIPMEC SEVEIQDTVK AGLQPLCAYR VLGRMFRRED NAKAVFIELA DTVNYTTLPS HIPGKGGSWE VVVKPRNPDD EFLSRLNYFL KDEGRSMTDV ARALGCCSLP AESLDAEVMP QVRSPPLEPP KESMWYRKLK VFSGTASPSP GEETFEDWLE QVTEIMPIWQ VSEVEKRRRL LESLRGPALS IMRVLQANND SITVEQCLDA LKQIFGDKED FRASQFRFLQ TSPKIGEKVS TFLLRLEPLL QKAVHKSPLS VRSTDMIRLK HLLARVAMTP ALRGKLELLD QRGCPPNFLE LMKLIRDEEE WENTEAVMKN KEKPSGRGRG ASGRQARAEA SVSAPQATVQ ARSFSDSSPQ TIQGGLPPLV KRRRLLGSES TRGEDHGQAT YPKAENQTPG REGPQAAGEE LGNEAGAGAM SHPKPWET
Explore Paraneoplastic antigen-like protein 5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets